Every material Form 8-K MiNK Therapeutics, Inc. has filed with the SEC since March 31, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
MiNK Therapeutics reported second-quarter 2026 results, with a net loss of $3.1 million, or $0.62 per share, compared with $4.2 million, or $1.06 per share, a year earlier. Cash and cash equivalents fell to $8.8 million as of June 30, 2026, down from $13.4 million at December 31, 2025, which matters to shareholders because it reflects the company's funding position.
Q2 2026 net loss was $3.1 million ($0.62 per share), down from $4.2 million ($1.06 per share) in Q2 2025.
Six-month net loss was $5.9 million ($1.20 per share), compared with $7.0 million ($1.76 per share) a year earlier.
Cash and cash equivalents were $8.8 million at June 30, 2026, versus $9.5 million at March 31, 2026 and $13.4 million at December 31, 2025.
The company attributes the year-over-year improvement to expense discipline; additional data from the C-1300-02 trial are expected in early 2027.
MiNK Therapeutics reported first quarter 2026 results on May 15, 2026. The net loss was about $2.7 million, or $0.57 per share, compared with about $2.8 million, or $0.70 per share, in the same period of 2025. Cash and cash equivalents fell to about $9.5 million from about $13.4 million at December 31, 2025, after the company repaid about $5.2 million on the Agenus convertible note.
Net loss of about $2.7 million, or $0.57 per share, for the quarter ended March 31, 2026, versus about $2.8 million, or $0.70 per share, a year earlier
Cash and cash equivalents of about $9.5 million at March 31, 2026, versus about $13.4 million at December 31, 2025
Repaid about $5.2 million on the Agenus convertible note; raised about $3.0 million through its at-the-market sales agreement in the quarter
Randomized Phase 2 trial of agenT-797 initiated, with preliminary data expected in the second half of 2026; ATS presentation scheduled for May 20, 2026
MiNK Therapeutics reported fourth-quarter and full-year 2025 results on March 31, 2026, along with a filing that furnishes its press release. The company's net loss widened for the full year, and it ended 2025 with $13.4 million in cash, which it says provides a runway through 2026 together with $3.0 million raised since year end under its at-the-market sales program.
Full-year 2025 net loss was $12.5 million, or $2.93 per share, compared with $10.8 million, or $2.86 per share, in 2024.
Fourth-quarter 2025 net loss was $2.6 million, or $0.56 per share, compared with $2.5 million, or $0.62 per share, in the fourth quarter of 2024.
Cash balance was $13.4 million at year end 2025; the company raised an additional $3.0 million through its at-the-market program after year end.
The press release cites a C-Further Consortium collaboration providing up to $1.1 million in non-dilutive funding; the filing reports no revenue figures.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every MiNK Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →